Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.46 |
| ▸ | CNR2 | P34972 | 11/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25086538 | 0.94 | CNR1 (0.45) | CNR1CNR2S1PR1DRD2DRD3 | |
| SCHEMBL18970401 | 0.90 | S1PR1 (0.45) | CNR1CNR2S1PR1DRD2GLA | |
| SCHEMBL19707534 | 0.84 | GRM4 (0.43) | CNR1CNR2S1PR1DRD2DRD3 | |
| SCHEMBL5545605 | 0.83 | CNR1 (0.43) | CNR1CNR2S1PR1GLA | |
| SCHEMBL14468209 | 0.83 | CNR1 (0.40) | CNR1CNR2S1PR1GLA | |
| SCHEMBL19683731 | 0.83 | TSHR (0.34) | CNR1CNR2S1PR1DRD2DRD3 | |
| SCHEMBL825570 | 0.83 | HDAC4 (0.49) | CNR1CNR2S1PR1GLA | |
| SCHEMBL22664587 | 0.83 | DRD2 (0.42) | CNR1CNR2S1PR1DRD2DRD3 | |
| SCHEMBL19003708 | 0.83 | DRD2 (0.42) | CNR1CNR2S1PR1DRD2DRD3 | |
| SCHEMBL28099989 | 0.82 | HDAC4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | CNR1 225/4885CNR2 181/4885S1PR1 590/4885 |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | CNR1 507/4885CNR2 925/4885S1PR1 915/4885 |
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | BAZ2A, BRD3, BRPF3 | CNR1 2557/4885CNR2 3163/4885S1PR1 3150/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | CNR1 225/4885CNR2 181/4885S1PR1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.